Floatz logo

ly4337713

Esophageal Neoplasms

Eli Lilly and CompanyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

130 Active assets in the Esophageal Neoplasms cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 4BB
Benadryl
Ciusss de L'Est de l'Île de Montréal
Phase 3B
Cyclophosphamide
Sutro Biopharma, Inc.
Phase 3B
Epirubicin
Sutro Biopharma, Inc.
Phase 3B

View all 50 →

Same molecule, other indications

ly4337713 is also rated in:

gastric neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
ovarian neoplasmDormant
C
Indicative ·
39 / 100
View asset →
colorectal neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →